Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lantern Pharma Inc.

3.17
+0.03000.96%
Volume:25.81K
Turnover:80.87K
Market Cap:34.19M
PE:-1.72
High:3.22
Open:3.17
Low:3.05
Close:3.14
Loading ...

Lake Street Keeps Their Buy Rating on Lantern Pharma (LTRN)

TIPRANKS
·
17 Jun

Lantern Pharma Inc. Announces Promising Results from HARMONIC Trial as Lung Cancer Patient Achieves Durable Complete Response with LP-300

Reuters
·
16 Jun

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions With Survival Continuing for Nearly Two Years

THOMSON REUTERS
·
16 Jun

Lantern Pharma: Anticipates Additional Data Update From Randomized Expansion Phase in H2 2025

THOMSON REUTERS
·
16 Jun

Lantern Pharma Inc - No Significant Adverse Drug Reactions Over 21 Cycles of Treatment

THOMSON REUTERS
·
16 Jun

Major Shareholders Offload Lantern Pharma Stock in Twin Transactions!

TIPRANKS
·
14 Jun

Aaron G.L. Fletcher, 10% Owner, Reports Disposal of Common Shares of Lantern Pharma Inc

Reuters
·
13 Jun

Leslie W. Kreis, 10% Owner, Reports Disposal of Lantern Pharma Inc. Common Shares

Reuters
·
30 May

Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025

Reuters
·
29 May

Lantern Pharma's Lp-184 Shows Promising in Vivo Activity in Atypical Teratoid Rhabdoid Tumors (Atrt) at Sno Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

THOMSON REUTERS
·
29 May

Lantern Pharma Advances AI-Driven Cancer Therapies

TIPRANKS
·
16 May

Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

THOMSON REUTERS
·
15 May

Lantern Pharma Q1 Net Income USD -4.5 Million

THOMSON REUTERS
·
15 May

Press Release: Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
15 May

Lantern Pharma Reports Q1 2025 Results: R&D Expenses Down to $3.3M, Cash Reserves at $19.7M

Reuters
·
15 May

Lantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate

Benzinga
·
15 May

Lantern Pharma Inc: Qtrly Shr Loss $0.42

THOMSON REUTERS
·
15 May

Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
13 May

Press Release: Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Dow Jones
·
08 May